Impact of showering on infection rates and quality of life after breast reconstruction
Official title: Effect of Drain Care on Infection Rate and Quality of Life in Implant-Based Breast Reconstruction.
Run by University of Missouri-Columbia · NCT05846438 · Data updated 2026-11-12
This study is testing if showering with drain tubes after breast reconstruction surgery affects infection rates and how patients feel during recovery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | University of Missouri-Columbia Academic / other |
| Locations | 1 site (Columbia, Missouri) |
| Status | Recruiting |
| Started | March 15, 2023 |
| Main results expected | March 15, 2028 |
| Study ends | March 15, 2028 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT05846438 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 undergoing breast surgery with tissue expander placement and drains.
✕Probably not a fit
Patients with existing wounds or previous infections related to implant devices may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates whether showering with surgical drain tubes in place after breast reconstruction surgery increases the risk of infection and affects patients' quality of life. Participants will be randomized into two groups: one group will shower daily after 48 hours post-surgery, while the other will follow the standard care of waiting until drains are removed. The study aims to provide insights into postoperative care practices and their implications for patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved postoperative care practices that enhance patient quality of life without increasing infection risks.
How similar studies have gone: While there is limited research specifically on showering with drains in place, similar studies have explored postoperative care practices, indicating potential for meaningful insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * undergoing breast surgery with placement of tissue expander and drains, acceptance of protocol and procedures, age \> 18 Exclusion Criteria: * no existing wounds, previous infections related to implant device if delayed, refusal by patient
Where it's running
-
University of Missouri
Columbia, Missouri, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Screen2Prevent: HIV screening for teens and young adults in emergency departments
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.